Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
Date:8/19/2009

w' target='_new' target='_new' href='http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=RODM'> RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the shares of Series 2 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 2 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC"). The shelf registration statement was automatically effective upon filing with the SEC. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of Series 2 Preferred Stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
6. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
7. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
10. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
11. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago this year, ... Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. The Academy ... Participants will have the opportunity to build a Free Flight fantasy club worthy of ...
(Date:7/23/2015)... ... 23, 2015 , ... July 23, 2015, Chicago - Advances ... options with fewer side effects, according to Erik P. Sulman, MD, PhD, associate ... the American Brain Tumor Association (ABTA) National Patient and Family Conference in Chicago, ...
(Date:7/23/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian ... Limited (Biohaven), are pleased to announce that Biohaven ... with the U.S. Food and Drug Administration (FDA) ... 54% equity interest in Biohaven, a private company. ... and Biohaven has entered into an exclusive worldwide ...
(Date:7/23/2015)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... and the general public to its Annual Shareholder Meeting ... 31, 2015. The meeting will be held at the ... San Diego, California 92121.   ... available. Please use the following link to register for ...
Breaking Biology Technology:Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4OncoSec to Webcast Annual Meeting of Stockholders 2
... fast and easy detection of mycoplasma,contamination , ... Staggs ,Genetic Applications LLC , Heinz Miller ,Stratagene , ... potency of transfection reagents. 1 Cells must be ... ,transfection reagent and ...
... using LipoTAXI transfection reagent , Peter ... Karmiol ,Clonetics Corporation, Walkersville, Maryland , LipoTAXI ... that offers,low cellular toxicity and high transfection ... is described for optimizing the amounts of ...
... transfection reagent: A proven choice , ... transfection reagent offers,improved, ... growing in,suspension. In this article, we summarize the ... LipoTAXI reagent. Optimizing transfection,conditions is a critical, preliminary ...
Cached Biology Technology:Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 2Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 4Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 2Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 3Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 4Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 6Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 7
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... natural selection favours traits that enhance dispersal of ... this theory, however, is relatively scarce. A study ... Biological and Environmental Sciences of the University of ... evolution of traits facilitating dispersal in an outer ...
... much iron is toxic, and can cause fatal organ failure. ... also be maintained. In a study published today in ... (EMBL) in Heidelberg, Germany, have discovered that a group of ... and as such are essential for cell survival. More specifically, ...
... ANN ARBOR, Mich.---In one of the first human studies ... the controversial chemical Bisphenol A, or BPA, may be related ... the researchers are quick to point out that these results ... documented adverse effects of BPA on semen in rodents, but ...
Cached Biology News:UH: Insular evolution: Large and big-footed voles in an outer archipelago 2Supply and demand 2Sperm may be harmed by exposure to BPA, study suggests 2
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
, Glycerol 30%...
Biology Products: